Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine.
In this study, we aimed to determine the modulatory effects of warfarin (an extensively used anticoagulant drug) and its metabolites on UDP-glucuronosyltransferase (UGT) activity and to assess the potential of warfarin to alter the pharmacokinetics of zidovudine (AZT). The effects of warfarin and its metabolites on glucuronidation were determined using human and rat liver microsomes (HLM and RLM) as well as expressed UGTs. The mechanisms of warfarin-UGT interactions were explored through kinetic characterization and modeling. Pharmacokinetic studies with rats were performed to evaluate the potential of warfarin to alter the pharmacokinetics of AZT. We found that warfarin was an effective modifier of a panel of UGT enzymes. The effects of warfarin on glucuronidation were inhibitory for UGT1A1, 2B7, and 2B17, but activating for UGT1A3. Mixed effects were observed for UGT1A7 and 1A9. Consistent with its inhibitory effects on UGT2B7 activity, warfarin inhibited AZT glucuronidation in HLM (Ki = 74.9-96.3 μM) and RLM (Ki = 190-230 μM). Inhibition of AZT glucuronidation by UGT2B7, HLM, and RLM was also observed with several hydroxylated metabolites of warfarin. Moreover, the systemic exposure (AUC) of AZT in rats was increased by a 1.5- to 2.1-fold upon warfarin coadministration. The elevated AUC was associated with suppressed glucuronidation that was probably attained through a combined action of warfarin and its hydroxylated metabolites. In conclusion, the activities of multiple UGT enzymes can be modulated by warfarin and the nature of modulation was isoform dependent. Also, pharmacokinetic interactions of zidovudine with warfarin were highly possible through inhibition of UGT metabolism.
Division of Pharmaceutics, College of Pharmacy, Jinan University, Guangzhou, 510632, China.
Hua
H
Sun
Tianpeng
T
Zhang
Zhufeng
Z
Wu
Baojian
B
Wu
D000818:Animals; D019380:Anti-HIV Agents / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology; D000925:Anticoagulants / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology; D001682:Biological Availability; D001711:Biotransformation / Q000187:drug effects; D004347:Drug Interactions; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D020719:Glucuronides / Q000097:blood / Q000378:metabolism; D014453:Glucuronosyltransferase / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D006900:Hydroxylation; D007527:Isoenzymes / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D007700:Kinetics; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D008954:Models, Biological; D011897:Random Allocation; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000378:metabolism; D014859:Warfarin / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000494:pharmacology; D015215:Zidovudine / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology
D019380:Anti-HIV Agents; D000925:Anticoagulants; D020719:Glucuronides; D007527:Isoenzymes; D011994:Recombinant Proteins; D015215:Zidovudine; D014859:Warfarin; D014453:Glucuronosyltransferase
UGT; bioavailability; drug-drug interactions; pharmacokinetics; phase II metabolism; warfarin; zidovudine